Although inflammation is central to gallbladder cancer (GBC) development and proliferation, no study has systematically investigated circulating inflammatory proteins and patient survival. We aimed to examine whether the circulating levels of inflammatory proteins is associated with all-cause mortality among such patients. We recruited 134 patients with newly diagnosed with GBC from 1997 to 2001 in a population-based study in Shanghai and an independent set of 35 patients from 2012 to 2013 in Chile. Cox proportional hazards regression models adjusted for covariates were used to evaluate the hazard ratios (HRs) for death by serum levels of 49 inflammatory proteins (quartiles). Of 49 evaluable proteins, eight were significantly associated with overall survival. Seven were associated with a poorer survival, while the highest levels of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were associated with an increase in survival (HR = 0.26, 95% CI = 0.14, 0.47). No substantial difference in the magnitude of the association was observed between early-and late-stages of GBC. Of seven proteins, five were validated in the patients from Chile. Reducing inflammation and targeting pathways associated with increased survival might improve GBC outcomes. The potential for using a TRAILrelated anticancer drug for GBC treatment merits further investigation.
The link between inflammation and gallbladder cancer risk is well established [13] [14] [15] [16] [17] , largely due to the fact that gallstones, which create extensive inflammation in the gallbladder, are the central risk factor for GBC 18 . Other potential risk factors are also likely act through inflammatory pathways, including diabetes, obesity, infections (e.g. Helicobacter species), metabolic syndrome, and other inflammation-related conditions [13] [14] [15] [16] [17] . However, the role of inflammation in the prognosis of GBC patients is largely unknown. Previous studies have reported associations with survival for only a limited number of inflammatory proteins representing a small subset of the inflammation cascade, such as C-reactive protein (CRP) 19, 20 , interleukin 6 (IL-6) 21 , and 17 (IL-17) 22 . However, previous studies are limited by single-center study design or lack of replication. Therefore, to systematically investigate whether circulating inflammatory proteins are related to GBC prognosis, we evaluated the association between circulating inflammatory proteins and overall survival among patients with GBC from Shanghai, China, where the age-standardized incidence rates of GBC are moderately high: ~3 per 100,000 person-years 23 , as opposed to ~1 per 100,000 person-years in the US 24 . We then verified the findings among patients from Chile, where the age-standardized incidence rates are among the highest in the world, reaching 8.6 and 24.3 per 100,000 person-years in males and females, respectively 3 .
Methods
Study population. Details of the Shanghai Biliary Cancer Study have been published previously 25 . Briefly, patients aged 35 to 74 years who were permanent residents of urban Shanghai with newly diagnosed primary biliary tract cancer (ICD 9 = 156) were identified through a rapid-reporting system established between the Shanghai Cancer Institute and 42 collaborating hospitals in 10 urban districts of Shanghai. Between June 1997 and May 2001, a total of 368 GBC cases were recruited, representing over 90% of all eligible GBC cases.
Because cholecystectomy (as a major treatment option) may affect the level of circulating inflammation proteins, of the 368 patients with GBC recruited, serum samples from 144 were tested for inflammatory proteins, including those who did not have cholecystectomy, or had serum collected prior to cholecystectomy. Vital status of all patients was identified through linkage to the Population Death Register until March 2003. Ten patients were excluded because of insufficient clinical (N = 2) or follow-up (N = 8) data, leaving 134 patients for analysis. We compared characteristics of patients who were included in this study versus those who were not included. No appreciable difference was noticed ( Supplementary Table 1 ).
We replicated the results from the Shanghai study in patients with GBC from the Chile Gallbladder Cancer Study, a study from which we had data on circulating inflammatory proteins and survival. Details about the Chile Gallbladder Cancer Study have been published 14, 26 . Briefly, between April 2012 and August 2013, we recruited 52 GBC cases newly diagnosed at cancer referral hospitals in Santiago, Concepción, and Temuco, with a participation rate of 85%. Thirty-five GBC cases with available serum samples and inflammation protein data were included in the validation study. Vital status of all GBC cases was identified through linkage to the Population Death Register until March 2017.
For both studies, written informed consent was obtained for biospecimen and questionnaire data collection for all participants. The Shanghai study was approved by the Institutional Review Boards of the National Cancer Institute and the Shanghai Cancer Institute. The Chile study was approved by Institutional Review Boards at the National Cancer Institute, Pontificia Universidad Católica de Chile, and the Chilean Ministry of Health. All methods were performed in accordance with the relevant guidelines and regulations. Laboratory Methods. All blood samples were continuously stored in freezers at −70 °C. In order to screen a large number of inflammation proteins, we tested these stored specimens using the recently-developed Luminex bead-based assay (EMD Millipore, Billerica, MA, USA) and, for acute phase markers, Meso Scale Discovery (MSD) Human Vascular Injury II kit (Meso Scale Diagnostics LLC, Rockville, MD, USA) 14, 15 . A total of 68 inflammatory proteins covering several key components of inflammation, including acute-phase proteins, pro-and anti-inflammatory cytokines, chemokines, growth factors, and angiogenesis factors were included. Details about these assays have been published 14, 15 , and the selection of the proteins is described in detail in Supplementary Materials. Briefly, we excluded 19 proteins with overall coefficients of variations >30%, intraclass correlation coefficients <0.75, and/or duplicated measurements. Thus, the final analysis of the Shanghai study included 49 evaluable proteins.
Statistical analyses.
We first identified inflammatory proteins that were associated with overall survival in the Shanghai study. Since subset of the samples from the Shanghai study were tested with a different lot of kits as described in the Supplemental Materials, study-specific cutpoints were used to generate categories. Because all proteins were detectable in all GBC cases, they were grouped into quartiles. Overall survival time was calculated from the date of sample collection (for 1 subject without recorded date of sample collection, date of diagnosis was used) until the date of death or last follow-up if a participant was still alive. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% CIs with overall survival. Age group at diagnosis (≤54, 55-65, or ≥66 years), sex, clinical stage (early [i.e., resectable, local, stages 1 and 2] or late [i.e., stages 3 and 4]), and whether the patient received a cholecystectomy were included in the minimally adjusted models because these variables have been previously reported to be associated with GBC survival 6,8,9 . In addition, we conducted stepwise linear regression to determine whether inflammation marker levels were associated with: education (none/primary, junior middle, senior middle, some college), ever drinking, ever smoking, self-reported body mass index (underweight, normal weight, overweight, obese), regular aspirin use (one year prior to interview), fasting status (fasting/not fasting), and history of hypertension, diabetes, kidney or bladder infection, tuberculosis, chronic gastritis, gastric ulcer, duodenal ulcer, appendicitis, coronary heart disease, and cholecystitis. For variables that were associated with proteins in linear regression, we considered whether the additionally included variables would change the minimally adjusted HR of overall survival for a SCIENTIFIC RePoRTS | (2018) 8:5671 | DOI:10.1038/s41598-018-23848-8 one-category increase in inflammatory protein level by more than 10%. Based on this criterion, no additional variables were included in the adjusted models. The proportionality of hazards assumption was examined by evaluating a time-dependent variable, which was the cross-product of treating marker categories as ordinal variables and time. No violation was observed after accounting for multiple testing. All models were stratified by lot.
Due to the potentially strong correlation between levels of inflammatory proteins and stage at diagnosis, for the Shanghai study we estimated median survival time adjusted for clinical stage using direct adjusted survival estimation with the mean of covariates method. The survival estimates were weighted by the overall proportion of patients with early-vs. late-stage GBC 27, 28 .
To test whether the association between proteins and overall survival differed by clinical stage or cholecystectomy, stratified analyses were performed. Heterogeneity across stratum was evaluated using the likelihood ratio test with and without interaction terms in the Cox proportional hazards regression model. At the time of analysis, we identified 4 samples that were collected after cholecystectomy. Thus, we also conducted analyses excluding these samples (N = 130). Growth of tumors after diagnosis could have affected levels. To the authors' knowledge, no information on the growth rate of gallbladder cancer has yet been published. Using the minimum doubling time reported for hepatocellular carcinoma as an example (doubling time ranging from 30 to 600 days) 29, 30 , we thus assumed the doubling time could be 30 days and performed a sensitivity analysis focusing on samples collected no more than 1 month after diagnosis (N = 108). We also conducted a backward step-wise regression model including all selected inflammatory proteins to determine the proteins independently associated with overall survival.
Inflammatory proteins associated with overall survival in the Shanghai study were also assessed in the Chile study 14 . The information on clinical stage was not complete for patients from Chile, so we used Cox proportional hazards regression models adjusted for sex and age at diagnosis. We did not adjust for cholecystectomy because 94% of patients (33 of 35) had surgical resection.
Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA) and R statistical software (http://www.r-project.org/). The statistical tests were two tailed with α = 0.05. For Shanghai study, Bonferroni corrected P values (0.05/49 = 0.001) were calculated to account for multiple testing.
Results
In the Shanghai study, unadjusted median survival was 5.1 months (interquartile range [IQR]: 1.8-15.9 months) for all patients, with 24.6 months (IQR: 9.3-47.8 months) for patients with early-stage and 3.7 months (IQR: 1.6-7.7 months) for patients with late stages ( Table 1 and Fig. 1A ). Patients with early-stage were more likely to have cholecystectomy. For all other patient characteristics, we found no appreciable differences between early-and late-stages. By the end of follow-up, 114 patients (85.1%) were deceased. Characteristics of the 35 patients from the Chile study have been published previously 14 . Unadjusted median survival was 9.9 months (IQR: 0.6-11.2 months).
Of the 49 inflammatory proteins in the Shanghai study, seven were statistically significantly associated with overall survival in patients with GBC in multivariable adjusted models (using P trend < 0.001, Bonferroni correction, Table 2 and Supplementary Table 2 ). Another one was at borderline significance (P trend = 0.001). (Table 2) . In contrast, elevated levels of TRAIL were associated with an increased survival (HR for Q4 vs Q1 = 0.26; 95% CI = 0.14, 0.47, P trend across marker categories = 8.3 × 10 −5 ). The median stage-adjusted survival time was 7.9 months longer in patients with the highest levels of TRAIL compared to those with the lowest levels ( Table 2) .
Of the eight proteins associated with survival, five (CCL19, CCL20, sTNFRI, sVEGFR3, and TRAIL) were not correlated with clinical stage ( Supplementary Table 3 ). Notably, in patients with early-stage GBC, poorer survival was associated with elevated levels of CCL19 (HR for one category increase = 1.58, 95% CI = 1.01, 2.48), CRP (HR = 1.39, 95% CI = 0.95, 2.04), IL-6 (HR = 1.53, 95% CI = 0.96, 2.45), sTNFRI (HR = 2.05, 95% CI = 1.17, 3.59), and sTNFRII (HR = 1.67, 95% CI = 1.09, 2.55, Fig. 2 ). In contrast, elevated levels of TRAIL were associated with an increased overall survival among patients with late-stage GBC (HR = 0.63, 95% CI = 0.51, 0.77) but not early-stage GBC (HR = 1.05, 95% CI = 0.65, 1.71). However, in multivariable adjusted survival models, no statistically significant interaction was observed between marker levels and either clinical stage (early-vs late-stage, all P interaction > 0.05) or cholecystectomy (yes vs no, all P interaction > 0.05). Only CCL19, sTNFRI, and TRAIL retained statistical significance (P < 0.05) in a backward step-wise regression model including all selected inflammatory proteins, partly due to the high correlation among selected inflammatory proteins (Table 3) .
In sensitivity analyses restricted to patients with blood collected before cholecystectomy and patients with blood collection no more than one month after diagnosis, we did not detect any appreciable changes in the magnitude of associations (Supplementary Tables 4 and 5) .
Of eight proteins associated with overall survival among GBC patients in the Shanghai study, seven had data available in the Chile study. We found that elevated levels of CCL20 (P trend across marker categories = 0.006), CRP (P trend = 0.033), sTNFRI (P trend = 0.014), and sTNFRII (P trend = 0.001) were associated with a poorer overall survival, while a higher level of TRAIL was still associated with an increased overall GBC survival (P trend = 0.015). 
Discussion
Using multiplexed assays, we conducted the most comprehensive analysis of systemic inflammatory proteins and GBC survival to date. We identified eight proteins that are associated with overall survival of patients with GBC after correcting for multiple testing. Seven proteins were associated with poorer survival, and one was associated with improved survival. Patients in the highest quartile of sTNFRII had a notably higher hazard for death compared with patients in the lowest quartile. On the other hand, patients in the highest quartile of TRAIL levels had a notably lower hazard for death compared with patients in the lowest quartile, and median survival times were ~8 months longer in patients in the highest quartile compared with patients in the lowest quartile. These results go beyond previously reported single-marker associations by demonstrating that multiple inflammatory proteins are important prognostic factors in patients with GBC.
We noticed a significant reduction in median overall survival time for seven inflammatory proteins, with the difference in survival for patients in Q4 vs Q1 ranging from 4.7 to 10.1 months. The magnitude of association with overall survival for these proteins (HR for Q4 vs. Q1 = ~3) is almost as strong as the clinical stage (HR for late-vs. early-stage = ~5), indicating the strong predictor ability of these proteins. Our findings on the associations with CRP and IL-6 are in line with other survival studies among GBC patients [19] [20] [21] . CRP is an acute-phase protein whose levels rapidly increase in response to most forms of inflammation. CRP has been included in the Glasgow prognostic score, which has been identified as an important prognostic factor for several malignancies, including GBC 20, 31 . CRP is an immediate downstream marker of IL-6, which is considered a key molecule in the progression of the chronic inflammatory process to carcinogenesis 32 . Higher circulation levels of IL-6 are also associated with tumor differentiation, local invasion, and poorer survival among patients with GBC 21 . In addition to these two proteins, we identified five other proteins associated with poorer overall survival (CCL19, CCL20, sTNFRI, sTNFRII, and sVEGFR3), of which 3 (CCL20, sTNFRI, sTNFRII) can be replicated in a separate study. CCL19 is highly expressed in human cancer cells, and ligand CCL19 binding to CCR7 induces actin polymerization and pseudopodia formation. Studies have shown that CCL19 is associated with features of more aggressive disease, such as higher histological grade for breast cancer 33 . It can also promote tumor growth and progression through activation of CCR7 34 . Associations between poorer survival among cancer patients and elevated systemic levels CCL20 has been reported, and their roles in tumor progression and metastasis have previously been recognized 34 . sTNFRI and sTNFRII are major receptors for tumor necrosis factor-alpha (TNF-α) and can act as inhibitors of the biological activity of TNF-α when present at elevated concentrations 35 . sVEGFR3 has been shown to play an important role in lymphangiogenesis and is thought to be involved in the development of lymph node metastasis 36, 37 .
Taken together, the large number of associations with inflammatory proteins may suggest inflammation has an essential role in survival among GBC patients. Therefore, controlling inflammation in these patients could potentially improve survival 38, 39 . For example, downregulation of the expression of IL-6 through adjuvant therapy has been proposed as an alternative therapeutic option in addition to radiotherapy or chemotherapy in clinical studies of other cancers 10, 40, 41 . Whether use of anti-inflammatory agents could improve survival in patients with GBC merits further investigation. Notably, TRAIL itself may have clinical utility. High expression of TRAIL is associated with favorable survival for cancers such as ovarian cancer and prostate cancer 42, 43 . The TRAIL system is critically involved in the surveillance and elimination of some tumor cells 44 . The in vivo importance of loss of sensitivity to TRAIL-mediated apoptosis has been demonstrated by clinical studies that have shown a correlation between low TRAIL receptor expression, poor prognosis, and tumor recurrence 45 . In addition, TRAIL knockout mice exhibit enhanced formation of metastases 46 . To our knowledge, this is the first study to show that elevated levels of TRAIL are associated with an increased GBC survival. The levels of TRAIL were not correlated with clinical stage (P = 0.79). Given that the median overall survival for patients with late-stage GBC is ~4 months, the 8-month increase in survival for patients in the highest TRAIL quartile compared to patients in the lowest quartile is substantial. TRAIL has been proposed as a promising anticancer drug because it can selectively induce apoptosis in cancer cells, but not in healthy cells 47 . Our results thus highlight the potential for using a TRAIL-related anticancer drug for GBC treatment.
The present study is the largest to date to investigate the circulating levels of a broad range of inflammatory proteins associated with GBC survival. Despite the small sample size, we identified eight prognosis-associated inflammatory proteins after multiple testing correction, of which five proteins were validated in an independent study conducted in a separate population. Although these two studies were conducted in independently different periods (one in the 1990s and one in the 2010s), given that patients from Shanghai were not compared directly with patient from Chile, we do not believe that the differences in study period would have resulted in any bias in the estimated associations. Differences in storage time may affect the levels of the circulating proteins. However, there is no reason to expect this degradation to be associated with survival or stage. The Shanghai study could potentially be attenuated due to cytokine degradation over time given the longer storage time for these samples, but the associations observed in the Shanghai and Chile studies were similar, suggesting that the results are not affected by the time in storage. In addition, most circulating inflammation markers are not affected by freeze-thaw cycles 48 , which is usually correlated with storage time, further alleviating concerns over sample integrity. However, our results should be interpreted in light of several methodologic limitations. Although there is strong biologic plausibility for the association of inflammatory proteins with GBC survival, our observations need replication given the large number of proteins evaluated with the potential for false positives. In addition, we used overall mortality data in our analyses, as opposed to GBC-specific mortality. Given that GBC is a highly lethal malignancy with overall cure rates of ~15%, however, overall mortality is likely a good surrogate for cancer-specific mortality. Clinical stage information was incomplete for the replication site, which may have introduced some bias due to uncontrolled confounding. Finally, the study populations used for the discovery and replication phases were ethnically heterogenous. It is unclear whether factors affecting overall survival would be expected to differ by ethnicity, but most associations replicated despite this heterogeneity, highlighting the robustness of our findings.
In conclusion, our study provides epidemiologic evidence for the association of acute-phase proteins, pro-inflammatory cytokines, chemokines, and growth factors with overall survival in GBC patients, pointing to a need for further evaluation of the role of inflammatory pathways preceding GBC and their involvement in disease severity and progression. Particularly, higher levels of TRAIL were independently associated with an improvement in survival among patients with GBC. TRAIL therefore merit further investigation. Nevertheless, because our data are observational, further studies among patients with GBC are required, including placebo-controlled trials of TRAIL-related anticancer drug or anti-inflammatory agents as adjuncts to other routine therapies.
